CA2339667C - Methode utilisant des composes de tetracycline afin d'augmenter une production d'interleukine-10 - Google Patents
Methode utilisant des composes de tetracycline afin d'augmenter une production d'interleukine-10 Download PDFInfo
- Publication number
- CA2339667C CA2339667C CA2339667A CA2339667A CA2339667C CA 2339667 C CA2339667 C CA 2339667C CA 2339667 A CA2339667 A CA 2339667A CA 2339667 A CA2339667 A CA 2339667A CA 2339667 C CA2339667 C CA 2339667C
- Authority
- CA
- Canada
- Prior art keywords
- dedimethylaminotetracycline
- tetracycline
- tetracycline derivative
- accordance
- cmt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne une méthode d'augmentation de la production endogène d'interleukine-10 dans les tissus et cellules de mammifères qui comprend l'administration d'une quantité efficace d'un dérivé de tétracycline. Cette méthode comprend aussi l'augmentation de la production d'interleukine-10 par administration d'une quantité efficace de dérivé de tétracycline à un mammifère. Des composés préférés de tétracycline sont ceux qui ont été modifiés afin de réduire ou d'éliminer leur activité antimicrobienne. Cette méthode peut être utilisée afin de traiter des conditions médicales chez des mammifères caractérisées par une production excessive d'IL-1 et de TNF.alpha..
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/151,534 US6015804A (en) | 1998-09-11 | 1998-09-11 | Method of using tetracycline compounds to enhance interleukin-10 production |
US09/151,534 | 1998-09-11 | ||
PCT/US1999/020972 WO2000015235A1 (fr) | 1998-09-11 | 1999-09-10 | Methode utilisant des composes de tetracycline afin d'augmenter une production d'interleukine-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2339667A1 CA2339667A1 (fr) | 2000-03-23 |
CA2339667C true CA2339667C (fr) | 2010-05-18 |
Family
ID=22539191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2339667A Expired - Fee Related CA2339667C (fr) | 1998-09-11 | 1999-09-10 | Methode utilisant des composes de tetracycline afin d'augmenter une production d'interleukine-10 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6015804A (fr) |
EP (1) | EP1119362B1 (fr) |
JP (3) | JP2002524521A (fr) |
KR (1) | KR100691654B1 (fr) |
AT (1) | ATE317262T1 (fr) |
AU (1) | AU754515B2 (fr) |
CA (1) | CA2339667C (fr) |
CY (1) | CY1107495T1 (fr) |
DE (1) | DE69929810T2 (fr) |
DK (1) | DK1119362T3 (fr) |
ES (1) | ES2258854T3 (fr) |
NZ (1) | NZ509799A (fr) |
PT (1) | PT1119362E (fr) |
WO (1) | WO2000015235A1 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429204B1 (en) * | 1997-01-15 | 2002-08-06 | University Of Miami | Method of inhibiting cancer growth |
US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
US6673843B2 (en) * | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
US20020132798A1 (en) * | 2000-06-16 | 2002-09-19 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
EP1383483A4 (fr) * | 2001-04-05 | 2006-08-09 | Collagenex Pharm Inc | Delivrance controlee de composes de tetracycline et de derives de tetracycline |
AU2002303250B2 (en) * | 2001-04-05 | 2006-05-25 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
EP2301550A1 (fr) | 2001-07-13 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | Composés de tétracycline dotés d'activités thérapeutiques |
US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
US20110092677A1 (en) * | 2001-08-30 | 2011-04-21 | Biorexis Technology, Inc. | Modified transferin-antibody fusion proteins |
EP2311799A1 (fr) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | Composés de tétracycline 4-dedimethylamino |
KR101014918B1 (ko) | 2002-03-08 | 2011-02-15 | 파라테크 파마슈티컬스, 인크. | 아미노-메틸 치환된 테트라시클린 화합물 |
CA2478522A1 (fr) * | 2002-03-08 | 2003-09-18 | Emory University | Nouvelles constructions de facteurs viia de curcuminoides utilisees en tant que suppresseurs de la croissance tumorale et de l'angiogenese |
IL164180A0 (en) | 2002-03-21 | 2005-12-18 | Paratek Pharm Innc | Substituted tetracycline compounds |
KR20040094833A (ko) * | 2002-03-29 | 2004-11-10 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 비-항균성 테트라사이클린 동족체의 용도 및 박테리아외독소의 치료를 위한 이의 제형 |
US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
US8192749B2 (en) | 2003-04-16 | 2012-06-05 | Galderma Laboratories Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
AU2003243205A1 (en) * | 2002-05-06 | 2003-11-17 | Collagenex Pharmaceuticals, Inc. | Methods of simultaneously treating mucositis and fungal infection |
KR101148415B1 (ko) | 2002-07-12 | 2012-05-21 | 파라테크 파마슈티컬스, 인크. | 3, 10, 및 12a 치환된 테트라시클린 화합물 |
PT2204168E (pt) * | 2003-04-07 | 2015-03-05 | Supernus Pharmaceuticals Inc | Formulações de tetraciclinas de dose única diária |
EA201100956A1 (ru) | 2003-07-09 | 2012-01-30 | Пэрэтек Фамэсьютикэлс, Инк. | Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта |
AU2004259661B2 (en) | 2003-07-09 | 2011-11-10 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
JP2007510757A (ja) * | 2003-11-06 | 2007-04-26 | ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク | 湿疹の治療方法 |
EP2332904A3 (fr) | 2004-01-15 | 2012-04-11 | Paratek Pharmaceuticals, Inc. | Derives des composes de tetracycline |
AU2005299294B2 (en) | 2004-10-25 | 2012-06-07 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
EP1807387A2 (fr) | 2004-10-25 | 2007-07-18 | Paratek Pharmaceuticals, Inc. | Composes de tetracycline substitues |
US20090209497A1 (en) * | 2005-05-16 | 2009-08-20 | Judah Folkman | Method of treating lymphangioleiomyomatosis (lam) |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
US8252776B2 (en) * | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
EP1910273A2 (fr) * | 2005-07-21 | 2008-04-16 | Paratek Pharmaceuticals, Inc. | Tetracyclines 10-substituees et leurs procedes d'utilisation |
BRPI0620430A2 (pt) * | 2005-12-22 | 2011-11-08 | Wyeth Corp | métodos para tratar infecções do trato gastrointestinal com tigeciclina |
WO2007075794A2 (fr) * | 2005-12-22 | 2007-07-05 | Wyeth | Formulations orales contenant de la tigecycline |
ES2463457T3 (es) | 2006-12-21 | 2014-05-28 | Paratek Pharmaceuticals, Inc. | Derivados de la tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias |
WO2008079363A2 (fr) | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Utilisation de composés à base de tétracycline substituée dans le traitement d'affections cutanées inflammatoires |
EP2213655A1 (fr) | 2007-04-27 | 2010-08-04 | Paratek Pharmaceuticals, Inc. | Procédés de purification de composés d'aminoalkyle de tétracycline |
JP2010532759A (ja) * | 2007-07-06 | 2010-10-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 置換テトラサイクリン化合物を合成するための方法 |
TW202216656A (zh) * | 2008-05-23 | 2022-05-01 | 美商Prtk Spv2公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
MX2011001367A (es) | 2008-08-08 | 2011-06-28 | Tetraphase Pharmaceuticals Inc | Compuestos de tetraciclina sustituidos con fluor en c7. |
US9315451B2 (en) | 2009-05-08 | 2016-04-19 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
EP3275861A1 (fr) | 2009-08-28 | 2018-01-31 | Tetraphase Pharmaceuticals, Inc. | Composés de tétracycline |
KR101879751B1 (ko) | 2010-03-31 | 2018-08-16 | 테트라페이즈 파마슈티컬스, 인코포레이티드 | 폴리사이클릭 테트라사이클린 화합물 |
US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
EP2890673B1 (fr) | 2012-08-31 | 2018-11-14 | Tetraphase Pharmaceuticals, Inc. | Composés de tétracyclines |
US20190002188A1 (en) * | 2015-06-30 | 2019-01-03 | Philip Morris Products S.A. | Container with improved opening |
CN110582486B (zh) | 2016-10-19 | 2024-01-12 | 四相制药公司 | 艾若威四环素的结晶形式 |
WO2020097450A1 (fr) | 2018-11-09 | 2020-05-14 | Tetraphase Pharmaceuticals, Inc. | Formes polymorphes d'un composé et utilisations associées |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4505896A (en) * | 1979-04-19 | 1985-03-19 | Elorac, Ltd. | Method of treating acne vulgaris and composition |
US4704383A (en) * | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
JP3016587B2 (ja) * | 1989-12-04 | 2000-03-06 | ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク | 非ステロイド抗炎症剤及びテトラサイクリンの配合 |
US5045538A (en) * | 1990-06-28 | 1991-09-03 | The Research Foundation Of State University Of New York | Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines |
US5258371A (en) * | 1992-05-29 | 1993-11-02 | Kuraray Co., Ltd. | Method to reduce connective tissue destruction |
US5368854A (en) * | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
DK0599397T3 (da) * | 1992-11-17 | 1996-09-16 | Univ New York State Res Found | Tetracycliner, herunder non-mikrobielle, kemisk-modificerede tetracycliner, inhiberer overdreven collagentværbinding ved diabetes |
US5665345A (en) * | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
US5726156A (en) * | 1995-03-06 | 1998-03-10 | Trega Biosciences, Inc. | Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels |
US5650396A (en) * | 1994-03-15 | 1997-07-22 | Celtrix Pharmaceuticals, Inc. | Methods of modulating inflammatory cytokines in the CNS using TGF-β |
EP0736302A3 (fr) * | 1995-03-23 | 1997-06-04 | Stichting Rega V Z W | Inhibiteurs de protéases, construction d'ADN pour l'expression d'une protéase et un procédé pour mesurer les protéases et/ou les inhibiteurs de protéases |
US5827840A (en) * | 1996-08-01 | 1998-10-27 | The Research Foundation Of State University Of New York | Promotion of wound healing by chemically-modified tetracyclines |
US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
US5837696A (en) * | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
JP2908375B2 (ja) * | 1997-04-01 | 1999-06-21 | ザ リサーチ ファンデーション オブ ステート ユニバーシティ オブ ニューヨーク | 非抗バクテリア性テトラサイクリン組成物 |
-
1998
- 1998-09-11 US US09/151,534 patent/US6015804A/en not_active Expired - Lifetime
-
1999
- 1999-09-10 AT AT99948198T patent/ATE317262T1/de active
- 1999-09-10 DK DK99948198T patent/DK1119362T3/da active
- 1999-09-10 AU AU61426/99A patent/AU754515B2/en not_active Ceased
- 1999-09-10 EP EP99948198A patent/EP1119362B1/fr not_active Expired - Lifetime
- 1999-09-10 JP JP2000569819A patent/JP2002524521A/ja active Pending
- 1999-09-10 NZ NZ509799A patent/NZ509799A/en not_active IP Right Cessation
- 1999-09-10 WO PCT/US1999/020972 patent/WO2000015235A1/fr active IP Right Grant
- 1999-09-10 PT PT99948198T patent/PT1119362E/pt unknown
- 1999-09-10 DE DE69929810T patent/DE69929810T2/de not_active Expired - Lifetime
- 1999-09-10 KR KR1020017002727A patent/KR100691654B1/ko not_active IP Right Cessation
- 1999-09-10 ES ES99948198T patent/ES2258854T3/es not_active Expired - Lifetime
- 1999-09-10 CA CA2339667A patent/CA2339667C/fr not_active Expired - Fee Related
-
2006
- 2006-04-07 CY CY20061100490T patent/CY1107495T1/el unknown
-
2009
- 2009-12-07 JP JP2009277751A patent/JP4929341B2/ja not_active Expired - Fee Related
-
2011
- 2011-05-06 JP JP2011103656A patent/JP2011148838A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69929810D1 (de) | 2006-04-20 |
CA2339667A1 (fr) | 2000-03-23 |
EP1119362A4 (fr) | 2003-03-12 |
JP2010053146A (ja) | 2010-03-11 |
DE69929810T2 (de) | 2006-11-02 |
US6015804A (en) | 2000-01-18 |
WO2000015235A1 (fr) | 2000-03-23 |
AU6142699A (en) | 2000-04-03 |
PT1119362E (pt) | 2006-06-30 |
JP4929341B2 (ja) | 2012-05-09 |
AU754515B2 (en) | 2002-11-21 |
JP2011148838A (ja) | 2011-08-04 |
EP1119362A1 (fr) | 2001-08-01 |
ATE317262T1 (de) | 2006-02-15 |
JP2002524521A (ja) | 2002-08-06 |
DK1119362T3 (da) | 2006-06-12 |
EP1119362B1 (fr) | 2006-02-08 |
ES2258854T3 (es) | 2006-09-01 |
CY1107495T1 (el) | 2013-03-13 |
KR100691654B1 (ko) | 2007-03-09 |
KR20010074919A (ko) | 2001-08-09 |
NZ509799A (en) | 2003-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2339667C (fr) | Methode utilisant des composes de tetracycline afin d'augmenter une production d'interleukine-10 | |
AU2002256092B2 (en) | Controlled delivery of tetracycline compounds and tetracycline derivatives | |
AU2002256092A1 (en) | Controlled delivery of tetracycline compounds and tetracycline derivatives | |
Last-Barney et al. | Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1. | |
US5459135A (en) | Composition comprising indomethacin [non-steroidal anti-inflammatory agent] and effectively non-antibacterial tetracycline to reduce bone loss | |
Mehta et al. | Inhibition by all-trans-retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages | |
EP0971585B1 (fr) | Tetracyclines pour traiter certains types de cancers | |
EP0586020A1 (fr) | Tetracyclines seules ou en combinaison avec NSAID pour le traitement de la destruction des tissus | |
JP3148284B2 (ja) | テトラサイクリン含有医薬組成物 | |
AU3823497A (en) | Promotion of wound healing by chemically-modified tetracyclines | |
NZ510628A (en) | Use of a tetracycline derivative for reducing the risk of cataract formation in a mammal | |
WO2006036655A2 (fr) | Utilisation de tetracyclines modifiees chimiquement a faible dose pour reduire les mediateurs inflammatoires | |
IE62398B1 (en) | A novel anti-collagenolytic formulation for the treatment chronic inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160912 |